Srinivas Akkaraju, Director at ALUMIS INC. (ALMS), bought 766,651 shares at $11.17 ($8.3M) on 2026-09-04, disclosed to the SEC on 2026-09-09.
Director Srinivas Akkaraju purchased $2.46M of ALMS shares at $11.17, signaling confidence in the stock's valuation following a steep post-trial selloff. This move comes as the stock trades near 52-week lows, presenting a potential contrarian entry point.
The stock has crashed 64.37% over the last 30 days and is down 5.13% in the past 5 days, currently trading at $9.80, which is 68.69% below its 52-week high of $31.30.
1) The company plans to advance Envudeucitinib based on subgroup data from the Phase 2b LUMUS trial (Sept 9, 2026). 2) The company plans to discuss potential regulatory paths for broader immune-mediated indications based on the subgroup data (Sept 3, 2026). 3) The stock is down 56.18% in the last 7 days following the Phase 2b LUMUS trial miss (Sept 3, 2026).
1) The Phase 2b LUMUS trial failed to meet primary or secondary endpoints in the overall population (Sept 9, 2026). 2) The stock is down 60.38% over the last 30 days following the trial miss (Sept 3, 2026). 3) The stock is down 56.18% in the last 7 days following the trial miss (Sept 3, 2026).
Clearly above the average filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $11.17 | 220,070 | $2.5M | 29.7% |
| 2 | $10.63 | 273,290 | $2.9M | 35.1% |
| 3 | $10.63 | 273,291 | $2.9M | 35.1% |
| Total | $10.78 avg | 766,651 | $8.3M | 100% |
| Filing → |
| SRRK | BUY | 2025-12-16 | $1.9M | — | Filing → |
| ALMS | BUY | 2025-12-09 | $3.7M | — | Filing → |
| ALMS | BUY | 2025-12-04 | $2.6M | — | Filing → |